library.onepin.app/tb-500 Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider

OnePin Peptide Library · Repair & Recovery

Repair & Recovery Synthetic peptide fragment Not FDA-approved · investigational

TB-500

TB500 · Thymosin Beta-4 Fragment · T-Beta-4

Synthetic peptide fragmentThymosin beta-4 related peptideActin-associated pro-migratory regenerative signaling peptideAnti-fibrotic and anti-inflammatory peptide

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4, a naturally occurring 43 amino acid protein involved in cell migration, wound repair, and tissue remodeling. The fragment is centered on the actin-binding domain and retains key regenerative signaling properties of the parent molecule. TB-500 is discussed primarily in the context of soft tissue recovery, angiogenesis, extracellular matrix modulation, and inflammatory pathway regulation. It regulates actin polymerization and F-actin formation, which is the molecular machinery that allows cells to migrate to injury sites. TB-500 also suppresses the NF-kB inflammatory pathway systemically. Its half-life of roughly two days means a single injection distributes repair signals across the entire body, distinguishing it from locally-acting peptides like BPC-157.

Quick Start
Route
SubQ is standard injectable route. Systemic distribution makes injection site less critical than BPC-157.
Start low
2 to 2.5 mg per week is commonly discussed
Frequency
Once or twice weekly for loading, once weekly for maintenance
Timing
No evidence-based fed or fasted requirement

Can be taken any time of day. No fasting required. Systemic distribution means injection site is less critical than BPC-157.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Quick Start
Conservative start
2 to 2.5 mg per week is commonly discussed · SubQ is standard injectable route. Systemic distribution makes injection site less critical than BPC-157. · Once or twice weekly for loading, once weekly for maintenance
Lowest starting point. Hold about a week to assess tolerance before stepping up.
2 to 2.5 mg per week is commonly discussed
Once or twice weekly for loading, once weekly for maintenance
Standard
Loading Phase
2.5 mg · SubQ · 2x Weekly
in vitro · Philp et al. 2003 (FASEB J)
2.5 mg
2x Weekly
Standard
Maintenance Phase
2.5 mg · SubQ · Weekly
anecdotal · community
2.5 mg
Weekly
Reconstitution CalculatorU-100
050100u
Draw to
units
01

How it works

TB-500 acts primarily through regulation of actin polymerization and cytoskeletal dynamics. By sequestering G-actin monomers, TB-500 controls the balance between monomeric and filamentous actin, which directly affects cell motility, shape, and migration capacity. This allows repair cells (fibroblasts, endothelial cells, stem cells) to migrate to injury sites more effectively. TB-500 also promotes angiogenesis through new blood vessel formation in damaged tissue, modulates inflammatory cytokine signaling via NF-kB pathway suppression, supports extracellular matrix deposition and remodeling, and influences laminin and fibronectin expression relevant to tissue scaffolding. Unlike BPC-157 which acts primarily locally, TB-500 distributes systemically due to its approximately 2-day half-life, providing whole-body repair signaling from a single injection.

TB-500 acts primarily through regulation of actin polymerization and cytoskeletal dynamics. By sequestering G-actin monomers, TB-500 controls the balance between monomeric and filamentous actin, which directly affects cell motility, shape, and migration capacity. This allows repair cells (fibroblasts, endothelial cells, stem cells) to migrate to injury sites more effectively. TB-500 also promotes angiogenesis through new blood vessel formation in damaged tissue, modulates inflammatory cytokine signaling via NF-kB pathway suppression, supports extracellular matrix deposition and remodeling, and influences laminin and fibronectin expression relevant to tissue scaffolding. Unlike BPC-157 which acts primarily locally, TB-500 distributes systemically due to its approximately 2-day half-life, providing whole-body repair signaling from a single injection.

02

What to expect

Early
Days 1–7

Days 1-14: Minimal perceptible changes during the first week or two. TB-500 works through gradual cell migration and tissue remodeling processes that take time to manifest. Some users report subtle improvements in flexibility.

Mid
Weeks 2–4

Weeks 2-6: Flexibility and mobility improvements become more noticeable. Joint stiffness begins to decrease. Recovery time between workouts shortens. Users with active injuries report functional improvement.

Later
Weeks 4–12

Weeks 6-12: Cumulative tissue remodeling effects become clearly apparent. Chronic injuries show significant improvement. Connective tissue quality improves. Anti-fibrotic effects manifest in reduced scar tissue stiffness. Reassess protocol goals at 8-12 weeks.

03

Evidence

HumanPresent
AnimalStrong
In-vitroStrong
1999Thymosin beta4 accelerates wound healing · Malinda KM et al, Journal of Investigative Dermatology ↗peer reviewed
2014The regenerative peptide thymosin beta4 accelerates the rate of dermal healing in preclinical animal models and in patients · Kim S, Kwon J, Annals of the New York Academy of Sciences ↗review
2007Development of thymosin beta4 for treatment of patients with ischemic heart disease · Crockford D et al, Annals of the New York Academy of Sciences ↗review
2010A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers · Ruff D et al, Annals of the New York Academy of Sciences ↗peer reviewed
04

The honest take

Hair growth

Thymosin beta-4 has been shown to promote hair follicle stem cell migration and differentiation in animal models. Anecdotal human reports of improved hair growth exist. Not a validated hair loss treatment.

Cardiac repair

Animal studies show thymosin beta-4 promotes cardiac repair post-myocardial infarction by activating epicardial progenitor cells. This is preclinical data and does not support cardiac treatment claims in humans.

Anti-aging

TB-500's tissue remodeling and anti-fibrotic properties are discussed in longevity contexts. No human anti-aging data exists. Monitoring only.

05

Interactions & stacking

What's safe to combine, and what belongs in a separate pin.

Safe & synergistic

AOD-9604Non-overlapping mechanisms
SS-31TB tissue repair + SS-31 mitochondrial support
LL-37TB repair + LL-37 antimicrobial
TA-1TB repair + TA-1 immune modulation

Keep separate

CJC-1295 with DACDAC maleimide group reactivity concern in syringe.
06

Side effects & safety

Commonly reported

  • Generally well tolerated
  • Mild injection site redness or swelling
  • Occasional headache, particularly during loading phase
  • Transient fatigue in some users during first few days

Less common & notes

  • Some users report a temporary flu-like feeling during the first week, possibly related to immune system modulation (thymosin beta-4 has immune-active properties).
  • Rare reports of lightheadedness.
  • Any signs of unusual swelling, persistent headache, or unexpected immune changes should prompt reassessment.
  • TB-500 is on the WADA prohibited list.
  • Long-term human safety data is not established.
07

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
2.5h
Peak · Tmax
1.5h
Elimination
12.5h
Activity
4-7 days (cell migration and tissue repair signaling persists; supports weekly dosing)

Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C), dry, and protected from light. After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28-30 days when stored properly. Do not freeze after reconstitution. Minimize repeated temperature cycling and needle punctures. Inspect before each use for particles, haze, or discoloration.

08

Regulatory status

WADA prohibits thymosin beta-4 and its fragments including TB-500 under S2 Peptide Hormones. FDA does not approve TB-500 for any human use. FDA classifies it as Category 2 for compounding purposes. Available through research chemical channels. Regulatory status should be verified against current governing body rules before use.

Put it to work

Calculate, log & track

Open TB-500 straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open TB-500 in the app →

Go deeper

The guide & community

The complete TB-500 walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community